Current and emerging therapies for alcohol-associated hepatitis

Simple item page
dc.article.numbere2023169
dc.contributor.authorIdalsoaga F.
dc.contributor.authorAyares G.
dc.contributor.authorDiaz L.A.
dc.contributor.authorArnold J.
dc.contributor.authorAyala-Valverde M.
dc.contributor.authorHudson D.
dc.contributor.authorArrese M.
dc.contributor.authorArab J.P.
dc.contributor.otherCEDEUS (Chile)
dc.date.accessioned2025-05-01T10:33:01Z
dc.date.available2025-05-01T10:33:01Z
dc.date.issued2023
dc.description.abstract© 2023 The Third Affiliated Hospital of Sun Yat-sen UniversityAlcohol-related liver disease (ALD) encompasses a spectrum of diseases caused by excessive alcohol consumption. ALD includes hepatic steatosis, steatohepatitis, variable degrees of fibrosis, cirrhosis, and alcohol-associated hepatitis (AH), the latter being the most severe acute form of the disease. Severe AH is associated with high mortality (reaching up to 30%–50%) at 90 days. The cornerstone of ALD, and particularly AH, treatment continues to be abstinence, accompanied by support measures such as nutritional supplementation and management of alcohol withdrawal syndrome (AWS). In severe AH with model for end-stage liver disease (MELD) score ≥21, corticosteroids can be used, especially MELD score between 25 and 39, where the highest benefit is achieved. Other key aspects of treatment include the early identification of infections and their associated management and the proper identification of potential candidates for liver transplantation. The development of new therapies based on the pathophysiology and mechanisms of liver injury are underway. This includes the modulation and management of the innate immune response, gut dysbiosis, bacterial translocation, and bacteria-derived products from the intestine. These hold promise for the future of AH treatment.
dc.description.funderCoca Cola Company
dc.description.funderFundación Bengoa
dc.description.funderInstituto Pensi/Hospital Infantil Sabara
dc.description.funderInstituto de Investigación Nutricional de Peru
dc.description.funderInternational Life Science Institute of Argentina
dc.description.funderUniversidad de Costa Rica
dc.description.funderPontificia Universidad Javeriana
dc.description.funderPontificia Universidad Católica de Chile
dc.description.funderUniversidad Central de Venezuela
dc.description.funderUniversidad San Francisco de Quito
dc.format.extent11 páginas
dc.fuente.origenScopus
dc.identifier.doi10.1016/j.livres.2023.03.002
dc.identifier.eisbn9780128194706
dc.identifier.eissn1549-7828
dc.identifier.isbn9783031764011
dc.identifier.issn25425684 20962878
dc.identifier.pubmedid40156360
dc.identifier.scieloidS0718-69242020000300109
dc.identifier.scopusidSCOPUS_ID:85151395926
dc.identifier.urihttps://doi.org/10.1016/j.livres.2023.03.002
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/103936
dc.identifier.wosidWOS:001059746900001
dc.information.autorucEscuela de Medicina; Diaz Piga Luis Antonio; 0000-0002-8540-4930; 179253
dc.information.autorucEscuela de Medicina; Arab Verdugo Juan Pablo; 0000-0002-8561-396X; 132745
dc.issue.numero2
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final46
dc.pagina.inicio35
dc.publisherSpringer
dc.relation.ispartofIntersections Interdisciplinary Research on Architecture, Design, City and Territory
dc.revistaLiver Research
dc.rightsacceso abierto
dc.subjectAlcohol use disorder (AUD)
dc.subjectAlcohol-associated hepatitis (AH)
dc.subjectAlcohol-related liver disease (ALD)
dc.subjectAUD treatment
dc.subjectCirrhosis
dc.subjectFibrosis
dc.subjectNutritional therapy
dc.subjectSteroids therapy
dc.subject.ddc620
dc.subject.deweyIngenieríaes_ES
dc.subject.ods11 Sustainable cities and communities
dc.subject.odspa11 Ciudades y comunidades sostenibles
dc.titleCurrent and emerging therapies for alcohol-associated hepatitis
dc.typeartículo
dc.volumen7
sipa.codpersvinculados179253
sipa.codpersvinculados132745
sipa.indexScopus
sipa.trazabilidadCarga WOS-SCOPUS;01-05-2025
Files
Collections
Artículos de revistas